September 4, 2014 | The English High Court ruled in support of Israeli company Teva Pharmaceutical Industries in their case against Astra-Zeneca, a multi-national pharmaceutical and biologics company. According to the court, Astra-Zeneca will not be allowed to change their patent for the smart indication of Symbicort in order to facilitate Teva’s upcoming European launch of is asthma treatment DuoResp Spiromax, using Teva’s Spiromax technology.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments